Feed

SER

Serina Therapeutics Inc

SER · AMEX

$2.39 +3.46% (+$0.08)

1M -12.17%

Market Cap $33.0M

P/E Ratio -

Div. Yield -

ROE 222.42%

Bulios Fair Price

$1.6

33.1% downside

Current Price

$2.39

Undervalued Fair Value Overvalued

According to Bulios Fair Price, SER is currently overvalued relative to its market price. How does it work?

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak

2/9

Valuation

93 /100

Cheap

P/B 1.76x

PEG N/A

P/S N/A

Growth

N/A

Rev. growth N/A

FCF growth N/A

Book val. growth N/A

Profitability

N/A

Net margin N/A

Op. margin N/A

FCF margin N/A

Quality

0 /100

Poor

ROE 222.42%

ROA 82.03%

Asset turnover 0.00x

Debt

69 /100

Low

Current ratio 6.65x

Int. coverage -101.85x

Debt/Equity 0.17x

Stability

1 /100

Unstable

Rev. volatility 363.57%

EPS volatility 237.11%

Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about SER

Online

About the company

Serina Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapeutic products using polymer drug conjugate (PDC) technology. This technology allows drugs to better target specific tissues or organs and extends their effect in the body.

Sector

Healthcare

Industry

Biotechnology

CEO

Steven A. Ledger

Employees

Headquarters

Huntsville

Upcoming events

18 NOV

Earnings

Upcoming earnings report

56d

⌘ K

StockBot Live

Market situation Wall Street

Tech lifts Nasdaq to a record as Dow and S&P 500 slip

Nasdaq +0.23% closes at a record on tech gains. S&P 500 -0.07% and Dow -0.59% slip as oil pares earlier losses.

Ask about this

StockBot knows 80,000+ stocks worldwide